Colon Cancer: Answers to your most common questions

Wednesday, April 17, 2019
CTCA Chat Rewind: Answers to your Colon Cancer questions Pt.1
Part 1 of the March 26 web chat with doctors from Cancer Treatment Centers of America.
Part 2 of the March 26 web chat with doctors from Cancer Treatment Centers of America.

Colorectal cancer is the fourth most common non-skin cancer in America and the second-leading cause of cancer deaths. But for many adults at average or low risk, colorectal cancer may be caught early and treated with positive outcomes, simply by following an appropriate screening regimen. Tune in Tuesday March 26, 2019 at 4:00 pm here on 6abc.com and get updates on new guidelines to get screened earlier and take advantage of a wider array of tests. Submit your question below, now!



Raman Battish,MD


Medical Director of Gastroenterology, CTCA Philadelphia



Dr. Raman Battish is the Medical Director of Gastroenterology at Cancer Treatment Centers of America (CTCA) in Philadelphia.



Prior to joining CTCA, Dr. Battish worked as an interventional endoscopist at a hospital in Philadelphia, and as a Clinical Assistant Professor at Drexel University College of Medicine.



Dr. Battish earned a medical degree from Jefferson Medical College in Philadelphia. Following medical school, he completed an internal medicine residency at Jefferson University Hospital. His perspective on cancer care was forever changed by his mother's personal battle with cancer during his medical training. Read more.





Arturo Loaiza-Bonilla,MD, MSEd, FACP


Vice Chair, CTCA Department of Medical Oncology



It was the compassionate, patient-centered approach to fighting cancer that attracted Dr. Arturo Loaiza-Bonilla to Cancer Treatment Centers of America (CTCA). He joined CTCA in Philadelphia, in May 2017, and is Vice Chair of CTCA's Department of Medical Oncology. He also serves as the hospital's Chief of Medical Oncology and Medical Director of Research.



"At CTCA, our research department works closely with the pharmaceutical and diagnostic industries. This collaboration helps us deliver innovative technologies and novel treatment options to our patients," says Dr. Loaiza-Bonilla. "Our clinical trials emphasize new targeted therapies, diagnostics, molecules and immunotherapy. Whenever possible, we incorporate these breakthroughs and technologies into treatment plans, tailored to each patient and their specific tumor type. This is personalized precision cancer treatment, the next dimension of cancer care." Read more.